

Thu 27 Apr
12:00 - 13:30 | **Registration**
Other

Thu 27 Apr
13:30 - 14:00 | **Welcome Address**
Auditorium Other

13:30 | **Welcome from the chairs**
Patrizia Bonadonna (Italy)

13:40 | **Welcome to Verona**
Gianenrico Senna (Italy)

13:45 | **Welcome from EAACI**
Stefano Del Giacco (Italy)

13:50 | **Welcome to DHM**
Mohamed Shamji (United Kingdom)

13:55 | **Welcome from the Local authorities**

Thu 27 Apr
14:00 - 14:30 | **Opening Lecture**
Auditorium Session

Chair : Antonino Romano (Italy)

14:00 | **Drug hypersensitivity: its place in allergy and in medicine, its challenge, its future**
Knut Brockow (Germany)

Thu 27 Apr
14:30 - 16:00

Session 1 - Immediate drug hypersensitivity

Auditorium Session

Chair : Knut Brockow (Germany), Mauro Pagani (Italy)

14:30 **Fake antigens: the true cause of drug induced anaphylaxis**

Werner Pichler (Switzerland)

15:00 **Anaphylaxis to drugs at first sight: where, how and to what does sensitization occur?**

Uta Jappe (Germany)

15:30 **Triggers and treatment of anaphylaxis to drugs - findings from the European network**

Kathrin Scherer Hofmeier (Switzerland)

Thu 27 Apr
16:00 - 16:30

Coffee break

Poster area/Exhibition Coffee break

Thu 27 Apr
16:30 - 17:30

Poster Discussion Session I - Only onsite

Poster area/Exhibition Poster

Chair : Carla Lombardo (Italy), Alessandra Arcolaci (Italy), Axel Trautmann (Germany), Cristobalina Mayorga (Spain), Kathrin Scherer Hofmeier (Switzerland), Andreas Bircher (Switzerland)

16:30 **Antigenic determinants of penicillin G: Study of chemical stability vs specific IgE recognition**

PDS114 María Isabel Montañez (Spain)

PDS129 **Risk stratification through extensive allergy work-up in COVID-19-mRNA vaccine allergic reactions**

Annick BARBAUD (France)

PDS33 **A case of hypersensitivity to Sugammadex on first exposure: is pre-sensitisation through the oral route to be considered?**

Fatema-Zahra El Rhermoul (United Kingdom)

PDS46 **Increased levels of complement FHR-4A and other Factor H-Related proteins during acute DRESS in Spanish patients**

Teresa Bellon (Spain)

PDS28 **Aspirin desensitization in patients with aspirin-sensitive chronic urticaria: Why not as therapeutics?**

Jaechun Lee (Korea, Republic of)

PDS73 **SDRIFE caused by Nitrofurantoin – a case report**

Neha Christian (United Kingdom)

- 16:36**
PDS42 **Usefulness of myeloid dendritic cells in cellular in vitro assays for evaluating immediate hypersensitivity reactions to betalactams**
Ruben Fernandez-Santamaria (Spain)
-
- PDS116 **Use of basophil activation test in allergy to Covid-19 mRNA vaccines**
Kevin Kammermann (Switzerland)
-
- PDS61 **Local anaesthetic - wrong suspect No 1**
Lenka Sedlackova (Czech Republic)
-
- PDS48 **Desensitization protocol to ivacaftor and a compound of elexacaftor/tezacaftor/ivacaftor in a delayed hypersensitivity reaction confirmed by LTT**
Patricia Mir-Ihara (Spain)
-
- PDS98 **Genetic susceptibility in Iodinated Contrast Media-Related Anaphylaxis**
Jeong-eun Yun (Korea, Republic of)
-
- PDS52 **Understanding the Patient Experience of Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) Syndrome: A Qualitative Study**
Kimberly Blumenthal (United States of America)
-
- 16:42**
PDS81 **Resensitization in suspected cephalosporin hypersensitivity reactions**
Alessandro Ghilarducci (Italy)
-
- PDS53 **Penicillin as a hidden allergen in perioperative anaphylaxis. A case report**
Lenka Sedlackova (Czech Republic)
-
- PDS110 **Characterisation of T-cell immunogenicity to difluorophenoglyoxal (DFPG)-modified peptides in healthy donors**
Paul Thomson (United Kingdom)
-
- PDS45 **AllergoOncology: Application of Basophil Activation Test (BAT) in cancer patient blood to detect hypersensitivity to approved drugs and to IgE therapeutics**
Jitesh Chauhan (United Kingdom)
-
- PDS70 **Delayed cutaneous hypersensitivity to anti-tuberculosis drugs: real-life evaluation 3 years after publication of French propositions for practical management**
Haudrey Assier (France)
-
- 16:48**
PDS5 **Point-of-care antibiotic allergy delabelling in a critical care setting**
Joseph De Luca (Australia)
-
- PDS112 **Outcomes of revaccination in patients with hypersensitivity to COVID-19 vaccine in a tertiary care hospital in Southern Thailand**
Thanutcha Mahathumnuchok (Thailand)
-
- PDS36 **A Rare Case of Human Serum Albumin Induced Anaphylaxis**
Giorgia Marta (Italy)
-
- PDS125 **CD8+CD103+ skin resident memory T cells are increased and possibly activated in DIHS/DRESS**
Toshiharu Fujiyama (Japan)

-
- PDS108 **Skin Test-guided Strategy to Select Alternative Iodinated Contrast Media in Patients with Immediate Hypersensitivity Reaction: A Prospective Confirmative Study**
Ji-Hyang Lee (Korea, Republic of)
-
- PDS15 **Generalized Fixed Drug Eruption secondary to etoricoxib**
Diogo Mota (Portugal)
-
- 16:54
PDS97 **Clinical outcome associated with beta-lactam allergy labels in hospitalized patients**
Rik Schrijvers (Belgium)
-
- PDS111 **Hypersensitivity to tetanus vaccine: retrospective analysis of medical records and tolerance of vaccines against SARS-CoV-2**
Jan Baros (Czech Republic)
-
- PDS27 **Management decisions in 2 iron hypersensitivity reactions**
Denisa Mihaela Nedelcu (Romania)
-
- PDS17 **The Role of In Vitro Testing in Pharmacovigilance for β -Lactam-induced Serum Sickness-Like Reaction**
Abdelbaset Elzagallaai (Canada)
-
- PDS69 **Anaphylaxis during drug provocation test**
Maria-Jose Sanchez-Gonzalez (Spain)
-
- PDS120 **Successful etanercept treatment for a refractory pediatric case with toxic epidermal necrolysis**
Ryoya Ohashi (Japan)
-
- 17:00
PDS72 **The PEN-FAST+: two additional criteria to improve negative predictive value for the penicillin allergy clinical decision rule PEN-FAST in adults**
Annick BARBAUD (France)
-
- PDS38 **The effect of surgery, anaesthesia and fluid administration on tryptase concentrations**
Louise Savic (United Kingdom)
-
- PDS49 **Drug Hypersensitivity Reactions in Patients with Cystic Fibrosis: Potential value of the Lymphocyte Toxicity Assay to Assess Risk**
Awatif Abuzgaia (Canada)
-
- PDS124 **The model of monitoring medication rechallenge system in the Queen Savang Vadhana Memorial hospital the Thai Red Cross Society**
Kessada Tunwongsa (Thailand)
-
- PDS29 **Successful desensitization to lenalidomide in a patient with Multiple myeloma and lenalidomide induced leukocytoclastic vasculitis**
Ines Fernandez Concha Llona (Spain)
-
- 17:06
PDS107 **Systematic delabeling of allergy to betalactamic antibiotics in the general population**
Lluís Marques (Spain)
-

- PDS131 **Onset of DRESS following COVID-19 vaccination: More than just a happenstance**
Alpana Mohta (India)
-
- PDS63 **Vitamin B12 allergy: a multi-centre study**
Fatema-Zahra El Rhermoul (United Kingdom)
-
- PDS127 **Patients with Naproxen-Induced Liver Injury Display T-cell Memory Responses Towards an Oxidative (S)-O-Desmethylnaproxen Metabolite**
Paul Thomson (United Kingdom)
-
- PDS43 **Diagnostic basophil activation test accuracy for platin salts and taxanes hypersensitivity**
Julia Rodriguez De Guzman (Spain)
-
- PDS55 **Features of liver injury according to culprit drugs in a series of DRESS patients**
Rosario Cabañas (Spain)
-
- 17:12**
PDS54 **Analysis of hypersensitivity reactions in children intravenously treated with ceftriaxone in General hospital Izola (Slovenia) in ten years**
Sonja Posega Devetak (Slovenia)
-
- PDS21 **In patients with NSAID-exacerbated airway disease (N-ERD), identification of acute-onset hypersensitivity reactions associated with SARS-CoV-2 vaccine**
Melek Cihanbeylerden (Turkey)
-
- PDS115 **Case report: A rare case of IgE mediated allergy due to Angiotensin converting enzyme inhibitors**
Ines Fernandez Concha Llona (Spain)
-
- PDS86 **Identification of additional genetic risk factors associated with allopurinol-induced severe cutaneous adverse reactions in HLA-B*58:01 carriers**
Daeun Lee (Korea, Republic of)
-
- PDS8 **MRGPRX2 transcript levels in peripheral blood leukocytes in patients with severe drug-induced hypersensitivity reactions**
Alicja Dziadowiec (Poland)
-
- PDS4 **Value of in situ patch tests, ROAT then challenges in fixed drug eruptions: 61 cases studied by the FISARD group**
Annick BARBAUD (France)
-
- 17:18**
PDS20 **Improving quality of life and patient-reported outcomes by penicillin allergy delabelling: the overlooked impact of chronic spontaneous urticaria**
Philip H. Li (Hong Kong)
-
- PDS32 **Antihistamines hypersensitivity: fact or fiction?**
Diogo Mota (Portugal)
-
- PDS99 **Granzyme B production by Th2 helper and NK cells improves the LTT test in patients with non-immediate drug hypersensitivity reactions**
Lars H. Blom (Denmark)
-

Thu 27 Apr
16:35 - 16:35

Display Only - Only Onsite
Poster

PD6 **Macrolide Hypersensitivity - Is it as rare as reported?**

Helena Pires Pereira (Portugal)

PD12 **Hypersensitivity to Local Anesthetics - A Single-Center Retrospective 2-year Analysis**

Helena Pires Pereira (Portugal)

PD1 **Contact dermatitis to cinchocaine – is local anesthetics cross-reactivity a problem?**

Inês Farinha (Portugal)

PD13 **Iodinated contrast media hypersensitivity: risk factors or not?**

Francisca Cunha (Portugal)

PD22 **Hypersensitivity to gadolinium-based contrast agents: A single-center retrospective analysis over 2 years**

João Cardoso Lopes (Portugal)

PD101 **Is the drug always to blame? Maybe not**

Patricia Quijada Morales (Spain)

PD119 **The secret in their eyes**

Gema Salas (Spain)

Thu 27 Apr

17:30 - 19:15

Session 2 - Clinical approach of drug allergy

Auditorium Session

Chair : Patrizia Bonadonna (Italy), Beatrice Maria Bilò (Italy)

17:30 **Does drug hypersensitivity last forever?**

Maria Jose Torres (Spain)

17:55 **Update on anaphylaxis to chemotherapy: symptoms and prevention**

Mauro Pagani (Italy)

18:20 **Update on desensitisation and need for provocation in hypersensitivity to molecules used for chemotherapy**

Ricardo Madrigal-Burgaleta (Spain)

18:45 **Penicillin allergy delabeling has a significant impact on subsequent antibiotic use**

OAS5

Sara Fransson (Denmark)

19:00 **PEG allergy and the role of avidity: lessons learned from basophil activation testing**

OAS6

Toon Ieven (Belgium)

Thu 27 Apr
17:30 - 19:20

Session 2 - Basic Science: Pathomechanism of delayed reactions

Room Polifunzionale Session

Chair : Werner Pichler (Switzerland), Riichiro Abe (Japan)

17:30 **Carbamazepine hypersensitivity reactions: structural insights and animal models**

Shuen-iu Hung (Taiwan)

17:55 **Analysis of drug reactivity in SCARs: single-cell RNA sequencing**

Doyoung Kim (Korea, Republic of)

18:20 **Immune checkpoint inhibitors enhance the reaction to another drug by different pathomechanisms from ordinary Stevens-Johnson syndrome/toxic epidermal necrolysis**

OAS1

Haruna Kimura (Japan)

18:35 **Clinical, In-vitro and Ex-vivo Evidence for the Role of Immune Checkpoint Inhibitors in Precipitating Compound Hypersensitivity**

OAS2

Sean Hammond (United Kingdom)

18:50 **T cell phenotype of patients with drug reaction with eosinophilia and systemic symptoms shows signs of chronic activation even after resolution**

OAS3

Lester Thoo (Switzerland)

19:05 **Evaluation of beta lactam challenge safety in delayed drug hypersensitivity patients with negative Cyto-LTT results**

OAS4

Oliver Hausmann (Switzerland)

Thu 27 Apr
19:30 - 20:00

Opening ceremony

Auditorium Other

19:30 **History of DHM**

Patrizia Bonadonna (Italy)

19:40 **History of ENDA**

Lene Heise Garvey (Denmark)

19:50 **Verona: Exploring the history and cultural Heritage**

Olivieri Francesco (Italy)

Thu 27 Apr
20:00 - 21:30

Welcome Reception - Only Onsite

Poster area/Exhibition Other

Fri 28 Apr
07:30 - 08:15 | **Session 3 - Meet the Expert 1 - Only Onsite**
Auditorium Session

07:30 **Reactions to vaccines including COVID-19**
Giovanna Zanoni (Italy)

Fri 28 Apr
07:30 - 08:15 | **Session 3 - Meet the Expert 2 - Only Onsite**
Room Polifunzionale Session

07:30 **Clinical approach to hypersensitivity reactions to intravenous iron preparations**
Esther Steveling (Switzerland)

Fri 28 Apr
07:30 - 08:15 | **Session 3 - Meet the Expert 3 - Only Onsite**
Room Convegni Session

07:30 **Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) hypersensitivity reactions**
Beatrice Maria Bilò (Italy)

Fri 28 Apr
08:30 - 09:30 | **Session 4 - Pro/Con Debate**
Auditorium Session

Chair : Knut Brockow (Germany), Patrizia Bonadonna (Italy)

08:30 **Is premedication required for radio contrast media hypersensitivity? - Pro**
Paul Greenberger (United States of America)

08:45 **Is premedication required for radio contrast media hypersensitivity? - Con**
Kathrin Scherer Hofmeier (Switzerland)

09:00 **Penicillin challenge without prior testing - Pro**
Kimberly Blumenthal (United States of America)

09:15 **Penicillin challenge without prior testing - Con**
Maria Jose Torres (Spain)

Fri 28 Apr
09:30 - 11:00

Session 5 - Severe Drug Hypersensitivity Reactions

Auditorium Session

Chair : Annick BARBAUD (France), Mohamed Shamji (United Kingdom)

09:30 **Severity score of DRESS/DIHS: a useful tool for assessing disease severity and predicting fatal outcome**

Yoshiko Mizukawa (Japan)

09:55 **Severe Cutaneous Adverse Reactions (SCARs) to anticonvulsants**

Andreas Bircher (Switzerland)

10:20 **MPE, DRESS or SJS to the same drug in different patients: Which factors drive the clinical manifestations of hypersensitivity reactions?**

Elizabeth Phillips (United States of America)

10:45 **Involvement of PANoptosis in keratinocyte cell death in Stevens-Johnson syndrome and toxic epidermal necrolysis**

OAS7

Riichiro Abe (Japan)

Fri 28 Apr
11:00 - 11:30

Coffee break

Poster area/Exhibition Coffee break

Fri 28 Apr
11:30 - 13:00

Session 6 - Management of patients with Clonal Mast cell Disease and drug allergy (clinical approach)

Auditorium Session

Chair : Roberta Zanotti (Italy), Patrizia Bonadonna (Italy)

11:30 **When to suspect Clonal Mast cell disorder?**

Massimiliano Bonifacio (Italy)

11:55 **Considerations on general anaesthesia in patients with mastocytosis**

Lene Heise Garvey (Denmark)

12:20 **Mastocytosis and drug allergy in children**

Karin Hartmann (Switzerland)

12:45 **Drug provocation tests safety in adult patients with clonal mast cell disorders**

OAS8

Francesca Nalin (Italy)

Fri 28 Apr
11:30 - 13:00

Session 6 - New technologies in drug hypersensitivity (basic science)

Room Polifunzionale Session

Chair : Elizabeth Phillips (United States of America), Werner Pichler (Switzerland)

11:30 **Use of new technological platforms in investigating the pathogenesis of drug hypersensitivity**
Chonlaphat Sukasem (Thailand)

11:55 **Imaging diagnosis of early stage of SJS/TEN using artificial intelligence**
Riichiro Abe (Japan)

12:20 **Nanotechnology- mimicking protein for IgE determination**
Maribel Montanez (Spain)

12:45 **Analysis of miRNAs expression in patients with NSAIDs- exacerbated respiratory disease**
OAS9
Aleksandra Wardzynska (Poland)

Fri 28 Apr
13:00 - 14:00

Lunch and Poster Discussion Session II - Only Onsite

Poster area/Exhibition Poster

Chair : Marina Atanaskovic-Markovic (Serbia), Giovanna Zanoni (Italy), Werner Pichler (Switzerland), Maria Jose Torres (Spain), Oliver Hausmann (Switzerland), Lene Heise Garvey (Denmark)

13:00 **Candidate HLA alleles for prediction of beta-lactam antibiotics-induced severe cutaneous adverse reactions**
PDS123
Nontaya Nakkam (Thailand)

PDS133 **Defining T-cell responses to SARS-CoV-2 COVID-19 vaccines in healthy donors and patients with vaccine-induced thrombosis and thrombocytopenia (VITT)**
Joshua Gardner (United Kingdom)

PDS64 **Sugammadex as a cause of perioperative hypersensitivity reactions**
Cosmin Boteanu (Spain)

PDS113 **Case report on cross reactivity among atypical neuroleptics shown by Cyto-LTT analysis**
Mhedi Belkoniene (Switzerland)

PDS78 **Low Dose Selective Cyclo-Oxygenase 2 (COX-2) Inhibitor with Antihistamine Premedication May Be Used As a Common Strategy in Managing Multiple Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Intolerant Reactors**
Mohammed Faizal Bakhtiar (Malaysia)

PDS85 **Development of cell culture methods to explore the immunogenicity of biological therapeutics**
Liam Farrell (United Kingdom)

13:06 **The use of basophil activation tests in clinical-laboratory investigations in patients with beta-lactam allergy**
PDS11
Marta Lomikovska, (Ukraine)

-
- PDS130 **Adverse reactions to COVID-19 vaccines: gastroesophageal reflux disease contributes to laryngopharyngeal symptoms that mimic anaphylaxis**
Blanka Kaplan (United States of America)
-
- PDS65 **One of the causes of perioperative hypersensitivity reaction: the antibiotics – our experience**
Cosmin Boteanu (Spain)
-
- PDS104 **Etoposide desensitization cases managing in Armenia**
Melanya Sahakyan (Armenia)
-
- PDS80 **An unusual case of amoxicillin-induced anaphylaxis with secondary ischemic proctocolitis**
Afonso Caires (Portugal)
-
- PDS34 **A difficult combination to manage: severe anaphylaxis and coronary syndrome**
Anna Ferrer Franco (Spain)
-
- 13:12**
PDS57 **Delabeling of penicillin allergy: Room for improvement**
Sara Fransson (Denmark)
-
- PDS66 **Implementation of the perioperative hypersensitivity reaction guidelines in our unit, Allergy Anesthesia Unit of Hospital Central de la Cruz Roja**
Cosmin Boteanu (Spain)
-
- PDS58 **Inclisiran-induced injection site urticarial plaque in a patient with multiple late type allergies to statins and the lipid lowering anti-PCSK9 antibody alirocumab**
Sophie Vandenberghe (Switzerland)
-
- PDS30 **Incidence of Hypersensitivity Reactions to Carboplatin in Patients with Ovarian and Breast Cancer in Armenia: Single center study**
Yelena Ghalachyan (Armenia)
-
- PDS19 **Sensitivity and specificity of Nexkin DSPT in intradermal tests for diagnosis of immediate hypersensitivity reactions**
María de la Paz Morales (Spain)
-
- 13:18**
PDS76 **Beta lactam avoidance significantly increases inpatients' length of stay**
Anthony Smith (Australia)
-
- PDS26 **Polyethylene glycol and polysorbate 80 skin tests in the context of an allergic risk assessment for hypersensitivity reactions to anti- SARS-CoV-2 mRNA vaccines**
Emanuele Nappi (Italy)
-
- PDS82 **A rare case of life threatening hypersensitivity reaction to rocuronium-sugammadex complex**
Valentina Gueli (Italy)
-
- PDS50 **Drug reaction with eosinophilia and systemic symptoms – untangling comorbid conditions from differential diagnoses**
Fabrícia Carolino (Portugal)
-

- PDS75 **Acetylsalicylic Acid Challenge or Desensitization in Sensitive Patients with Cardiovascular Disease**
Gabriele Cortellini (Italy)
-
- PDS109 **Drug Hypersensitivity Quality of Life Questionnaire for Chinese: translation and validation**
Philip H. Li (Hong Kong)
-
- 13:24 PDS106 **Characteristics of patients with beta-lactam allergy stratified according to diagnostic risk – are there any new suggestions when delabeling procedures should be performed?**
Joanna GLÜCK (Poland)
-
- PDS132 **Adherence to the COVID-19 vaccine in high-risk patients following allergy work-up: do patients have faith in allergy testing?**
Florian Stehlin (Canada)
-
- PDS87 **Full dose neuromuscular blocking agent provocation testing: a case report**
Anna Littlejohns (Ukraine)
-
- PDS60 **Clinical observation: Immediate and delayed type hypersensitivity to the same drug**
Stefan Woehrl (Austria)
-
- PDS59 **Prescribing pattern of Cox-2 inhibitors in patients with a history of allergy to conventional NSAIDs in hospital belong to the Thai Red Cross Society**
Karunrat Tewthanom (Thailand)
-
- PDS10 **Allergy to Heparins**
Diana Pérez-Alzate (Spain)
-
- 13:30 PDS77 **Tolerance of penicillin in patients with confirmed delayed hypersensitivity reactions to aminopenicillins**
Ibtihal Alotaibi (Saudi Arabia)
-
- PDS68 **Perioperative anaphylaxis: three-year single-center survey**
Ana Luísa Moura (Portugal)
-
- PDS118 **Case report of a confirmed clindamycin delayed hypersensitivity using both in vivo and in vitro diagnostic tests**
Daniel Yerly (Switzerland)
-
- PDS134 **Successful oral dasatinib desensitization in an immediate hypersensitivity reaction**
Maria Ruano-Zaragoza (Spain)
-
- PDS44 **Anaphylactic shock with cardiopulmonary resuscitation due to SonoVue®: an emergent ultrasound contrast agent to be monitored**
Giovanna Araujo-Sánchez (Spain)
-
- 13:36 PDS16 **Different patterns of reactivity in immediate hypersensitivity to cephalosporins from a tertiary hospital centre**
Inês Farinha (Portugal)
-

- PDS35 **Incidence of Perioperative Hypersensitivity Reactions in Spanish Hospitals Group**
Jose Julio Laguna Martinez (Spain)
-
- PDS47 **Three cases of delayed hemodynamic disorders after drug provocation test for delayed hypersensitivity reactions**
Annick BARBAUD (France)
-
- PDS105 **Hypersensitivity to non-steroidal anti-inflammatory drugs in pediatric population**
Sandra Melissa Ramos-Rodriguez (Spain)
-
- PDS9 **Trends in drug allergy referrals to an Allergy department: shift in a decade (TRADE study)**
Afonso Caires (Portugal)
-
- 13:42
PDS71 **Delayed hypersensitivity reactions to clavulanate – Are there irritating concentrations in skin tests?**
Anabela Lopes (Portugal)
-
- PDS3 **Investigation of perioperative reactions: is it allergies or something else?**
Elisa Boni (Italy)
-
- PDS67 **A Case Report on Stevens-Johnson Syndrome Caused by Carbamazepine**
Tatevik Aloyan (Armenia)
-
- PDS31 **A clinical approach to a high-risk patient with cardiac comorbidities and a history of drug-induced anaphylaxis**
Cristian Budica (Romania)
-
- 13:48
PDS37 **Cefuroxime allergy: A retrospective case-series**
Evelyn Gutiérrez (Spain)
-
- PDS79 **Uncommon Manifestation: Erythema Multiforme Shows as Acute Urticaria**
Tatevik Aloyan (Armenia)
-
- PDS84 **MAIT Cells in Blood of Severe Cutaneous Drug Reactions Patients: Cytotoxic and Exhausted Phenotype with In vitro Responsiveness to Associated Drug**
Olivia Hernández-Jaimes (Mexico)
-

Fri 28 Apr
14:00 - 15:30

Session 7 - Immunology beyond drug allergy

Auditorium Session

Chair : Dean Naisbitt (United Kingdom), Cristobalina Mayorga (Spain)

14:00 **Risk T cell hybridomas with drug specific TCR: tools for mechanistic insights and risk assessment**
Daniel Yerly (Switzerland)

14:30 **Possible tolerance mechanism in drug hypersensitivity**
Montserrat Puig (United States of America)

15:00 **Characterisation of T-cell responses to drug haptens in patients with adverse reactions**
Dean Naisbitt (United Kingdom)

Fri 28 Apr
15:30 - 16:00

Coffee break

Poster area/Exhibition Coffee break

Fri 28 Apr
16:00 - 18:00

Session 8 - Delayed hypersensitivity reactions (clinical approach)

Auditorium Session

Chair : Patrizia Bonadonna (Italy), Lene Heise Garvey (Denmark)

16:00 **How to perform provocation test in delayed drug allergy?**
Annick BARBAUD (France)

16:30 **Accelerated diagnosis in Drug Allergy (AiDA) using a cytokine-based lymphocyte transformation test**
Oliver Hausmann (Switzerland)

17:00 **DRESS and Multiple Drug Hypersensitivity: clinical signs and T cell/cytokine reactivity**
Lukas Jörg (Switzerland)

17:30 **Glycolytic switching: an early indicator for vancomycin-specific T-cell activation**
OAS10
Joshua Gardner (United Kingdom)

Fri 28 Apr
16:00 - 18:00

Session 8 - New approaches in Drug Hypersensitivity

Room Polifunzionale Session

Chair : Mauro Pagani (Italy), Alessandra Arcolaci (Italy)

16:00 **Biologicals for treatment of SJS/TEN**

Chung Wen Hung (Taiwan)

16:30 **Use of anti-IL-5/anti IL-5R in DRESS**

Yongxing Fang (Switzerland)

17:00 **New in-vitro approaches for immediate hypersensitivity**

Cristobalina Mayorga (Spain)

17:30 **Treatment of drug reaction with eosinophilia and systemic symptoms with tofacitinib: a pilot study with dynamic cytokines profiles investigation**

OAS11

Shu-Hao Li (Taiwan)

Saturday 29 April

DHM 2023

Sat 29 Apr
07:30 - 08:15

Session 9 - Meet the Expert 4 - Only Onsite

Auditorium Session

07:30 **"Treating through" in drug hypersensitivity**

Axel Trautmann (Germany)

Sat 29 Apr
07:30 - 08:15

Session 9 - Meet the Expert 5 - Only Onsite

Room Polifunzionale Session

07:30 **Management of hypersensitivity to biologicals: diagnosis and prevention**

Alessandra Vultaggio (Italy)

Sat 29 Apr
07:30 - 08:15

Session 9 - Meet the Expert 6 - Only Onsite

Room Convegni Session

07:30 **Desensitization to antibiotics in targeted populations: children, cystic fibrosis, neutropenic patients**

Josefina Cernadas Rodrigues (Portugal)

Sat 29 Apr
08:30 - 09:30

Session 10 - Clinical Case 1

Auditorium Session

Chair : Maria Jose Torres (Spain)

08:30 **Hypersensitivity reactions to Proton Pump Inhibitors: diagnostic accuracy of skin and oral provocation test**

Carla Lombardo (Italy)

Sat 29 Apr
08:30 - 09:30

Session 10 - Clinical Case 2

Room Polifunzionale Session

08:30 **Perioperative allergy – what to suggest when skin tests are negative?**

Lene Heise Garvey (Denmark)

Sat 29 Apr
09:30 - 11:00

Session 11 - Role of the MRGPRX2 receptor for immediate non allergic drug hypersensitivity reactions

Auditorium Session

Chair : Didier Ebo (Belgium), Patrizia Bonadonna (Italy)

09:30 **MRGPRX2 occupancy on mast cells**

Mateusz Kwitniewski (Poland)

09:55 **MRGPRX2: Basophils versus mast cells**

Jessy Elst (Belgium)

10:20 **MRGPRX2: physiological action and role of the polymorphism in drug reactions**

Grzegorz Porebski (Poland)

10:45 **Meglumine gadoterate induces immunoglobulin-independent human mast cell activation and MRGPRX2 internalization**

OAS12

Paula Hernández Ruiz de Azcárate (Spain)

Sat 29 Apr
11:00 - 11:30

Coffee break

Poster area/Exhibition Coffee break

Sat 29 Apr
11:30 - 13:00

Session 12 - Drug allergy in children (clinical approach)

Auditorium Session

Chair : Marina Atanaskovic-Markovic (Serbia), Beatrice Maria Bilò (Italy)

11:30 **Penicillin allergy delabelling in children**

Jean-Christoph Caubet (Switzerland)

11:55 **NSAIDs hypersensitivity reactions in children?**

Francesca Mori (Italy)

12:20 **Hypersensitivity reactions to antiepileptic drugs in children**

Marina Atanaskovic-Markovic (Serbia)

Sat 29 Apr
11:30 - 13:00

Session 12 - From recent knowledge on pathomechanisms to the bedside (basic science)

Room Polifunzionale Session

Chair : Riichiro Abe (Japan), Werner Pichler (Switzerland)

11:30 **Novel mechanism of keratinocyte death in SJS/TEN**

Youichi Ogawa (Japan)

11:55 **Flow-based allergen testing: can mast cells beat basophils?**

Didier Ebo (Belgium)

12:20 **Pharmacogenetic and immunogenetic risk assessment in pharmaceutical studies and daily clinic: where do we stand now?**

Munir Pirmohamed (United Kingdom)

12:45 **Macromolecular structure of insulin impacts IgE-mediated activation of sensitized basophils**

OAS14
Anders Millner (Denmark)

Sat 29 Apr
13:00 - 13:15

Closing and Prize Giving Ceremony

Auditorium Other

13:00 **Closing and Prize Giving Ceremony**

Patrizia Bonadonna (Italy), Gianenrico Senna (Italy), Lene Heise Garvey (Denmark), Stefano Del Giacco (Italy), Mohamed Shamji (United Kingdom)